Meta-analysis of the role of bevacizumab in extensive stage small cell lung cancer. - Wikidata - awgldk - TriplyDB

Meta-analysis of the role of bevacizumab in extensive stage small cell lung cancer.

Meta-analysis of the role of bevacizumab in extensive stage small cell lung cancer.

http://www.wikidata.org/entity/Q33443519

about

Meta-analysis of the role of bevacizumab in extensive stage small cell lung cancer.

http://www.wikidata.org/entity/Q33443519

description

2017 nî lūn-bûn

@nan

2017 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2017 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

name

Meta-analysis of the role of bevacizumab in extensive stage small cell lung cancer.

@ast

Meta-analysis of the role of bevacizumab in extensive stage small cell lung cancer.

@en

type

label

Meta-analysis of the role of bevacizumab in extensive stage small cell lung cancer.

@ast

Meta-analysis of the role of bevacizumab in extensive stage small cell lung cancer.

@en

prefLabel

Meta-analysis of the role of bevacizumab in extensive stage small cell lung cancer.

@ast

Meta-analysis of the role of bevacizumab in extensive stage small cell lung cancer.

@en

P1433

Q33443519-52B3E1C4-0781-4ACD-9890-665A9E3021CC

P1476

Q33443519-32DC27ED-BF4A-4FBA-8A8C-5D1DE5184BA1

P2093

Q33443519-07DDA0ED-65C9-4DA2-9231-9468FABE5052

Q33443519-0A1801DC-ED09-4B65-8254-647C20C1BF88

Q33443519-1B553CD6-8B0C-4EF9-9C3A-B0DDEBFD9577

Q33443519-3689075A-E633-4B9A-BF48-62C2467DFE3F

Q33443519-647EAEFE-2041-429D-B0B4-29F081820635

Q33443519-844E4FE0-5C1E-4543-AF86-9D87A3C18FEF

Q33443519-97E7AC4D-2B9E-4306-951F-8DD908885E89

Q33443519-C999ADDE-E3C6-47A7-9009-DE42920B076D

Q33443519-D51A5ED8-D8EA-449C-A563-41A360073FC8

P2860

Q33443519-0AE91E8D-00AC-4450-9F1F-7FAE499246AF

Q33443519-249CE972-CD2A-48EB-952F-6ED69212D6B0

Q33443519-27C4CABA-29E8-42D8-ABF8-779DB4B02205

Q33443519-27DEF676-2F3E-4276-BE36-B41CF9614614

Q33443519-2BE26D6D-D8EE-42A0-9EEC-3934EAF7DD69

Q33443519-3B3A1DF8-C3EF-4D8A-9B95-74948F6DC759

Q33443519-3D752963-192D-4BD3-93A2-6FA4E1C1AB1A

Q33443519-425BFED3-767C-4931-B671-3F99409F6B40

Q33443519-43896B31-CC1F-423F-A56A-C15E9CCF94A8

Q33443519-4748BA94-8AC6-4FEA-85A1-50F1B387AED4

P304

Q33443519-799D9184-F425-4B19-BDB4-5485AD7F433A

P31

Q33443519-4264DB7A-FCD2-429D-AF7B-41802A0A286A

P356

Q33443519-6D2F2405-3ACB-4228-89AB-9696FF61D886

P433

Q33443519-BB765586-447B-4E2F-8F10-E6EF99E2325F

P478

Q33443519-9B5CB857-EE40-4D91-8460-D1A492465462

P577

Q33443519-3D7A0808-05CB-484D-A4D1-05178A41B264

P698

Q33443519-3ECC4C0E-0C26-4120-8723-842DAD049B91

P921

Q33443519-D47857D9-D21A-481E-ADEE-43F196416B60

P932

Q33443519-FBBD60B2-B9D2-4430-9F89-A1B9978F0C81

P356

P1433

Oncology Letters

P1476

Meta-analysis of the role of bevacizumab in extensive stage small cell lung cancer.

@en

P2093

Hai-Bo Zhang

http://www.w3.org/2001/XMLSchema#string

Jian-Ping Bai

http://www.w3.org/2001/XMLSchema#string

Li-Rong Liu

http://www.w3.org/2001/XMLSchema#string

Xian Chen

http://www.w3.org/2001/XMLSchema#string

Xin Qu

http://www.w3.org/2001/XMLSchema#string

Yan-Chun Qu

http://www.w3.org/2001/XMLSchema#string

Yan-Juan Zhu

http://www.w3.org/2001/XMLSchema#string

Yi-Hong Liu

http://www.w3.org/2001/XMLSchema#string

Yong Li

http://www.w3.org/2001/XMLSchema#string

P2860

Phase II study of cisplatin plus etoposide and bevacizumab for previously untreated, extensive-stage small-cell lung cancer: Eastern Cooperative Oncology Group Study E3501

Cancer statistics, 2008

Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer.

Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer.

Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer.

Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer.

Randomised phase III trial of carboplatin plus etoposide vs split doses of cisplatin plus etoposide in elderly or poor-risk patients with extensive disease small-cell lung cancer: JCOG 9702

Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124.

Phase II trial of irinotecan, carboplatin, and bevacizumab in the treatment of patients with extensive-stage small-cell lung cancer.

Cisplatin, irinotecan, and bevacizumab for untreated extensive-stage small-cell lung cancer: CALGB 30306, a phase II study.

P304

655-664

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3892/OL.2017.6249

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

14

http://www.w3.org/2001/XMLSchema#string

P577

2017-05-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28693218

http://www.w3.org/2001/XMLSchema#string

P921

P932

5494762

http://www.w3.org/2001/XMLSchema#string